Sunday 18 October 2026
Export OBIO’s income statement to Excel — free account
Orchestra BioMed Holdings, Inc.
OBIO Healthcare Biotechnology
Orchestra BioMed Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.5 million, up 1,169.2% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS grew 24.0%, free cash flow fell 25.9% and total debt rose 142.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.45
0.29
−5.05%
Follow OBIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.62 | 8.15 | 5.92 | 45.93 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.26) | (12.02) | (87.29) | (8.90) | |
P/B ratio |
14.27 | 6.47 | 3.70 | 2.96 | |
Price to Tangible BV |
14.27 | 6.47 | 3.70 | 2.96 | |
EV/Sales |
6.27 | 5.70 | 3.16 | 16.97 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.44) | (3.42) | (2.16) | (0.79) | |
EV/FCF |
(3.39) | (3.39) | (2.14) | (0.79) | |
Quick Ratio |
8.17 | 6.90 | 6.37 | 4.64 | |
Current Ratio |
8.26 | 7.03 | 6.45 | 4.73 | |
Net Debt/EBITDA |
3.38 | 3.65 | (13.37) | 4.05 | |
Debt/Assets |
30.11% | 14.24% | 12.42% | 13.55% | |
Debt/Equity |
1.80 | 0.35 | 0.27 | 0.32 | |
Asset Turnover |
0.40 | 0.41 | 0.35 | 0.03 | |
Operating CF/Net income |
0.80 | 1.07 | (0.38) | 0.70 | |
Capex/Depreciation |
(1.58) | (1.19) | (0.23) | (2.21) | |
Research and Development Expense of Revenue |
18,852.27% | 14,346.36% | 54.41% | 1,629.15% | |
Selling, General and Administrative Expense of Revenue |
6,623.86% | 5,793.64% | 23.58% | 824.39% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2,846.59% | 2,591.82% | 8.89% | 349.94% | |
Graham Net Nets |
0.05 | 0.14 | 0.24 | 0.28 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.68%) | (22.82%) | (27.23%) | (73.39%) | |
Free Cash Flow Yield |
(21.44%) | (20.66%) | (24.96%) | (46.97%) | |
Revenue per Share |
0.00 | 0.00 | 0.65 | 0.02 | |
Operating CF per Share |
(0.30) | (0.35) | (0.05) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.31) | (0.36) | (0.05) | (0.28) | |
Cash per Share |
1.72 | 1.51 | 2.23 | 1.84 | |
Shareholders Equity per Share |
0.30 | 0.66 | 1.12 | 0.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.30 | 0.66 | 1.12 | 0.84 | |
Free Cash Flow |
(19.59) | (22.35) | (2.30) | (14.86) | |
Working Capital |
97.77 | 82.52 | 91.18 | 77.11 | |
Capital Expenditures |
(0.25) | (0.18) | (0.03) | (0.31) | |
Net Current Asset Value |
14.86 | 36.74 | 46.62 | 36.70 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
2.89 | 1.67 | 0.00 | 0.36 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.07 | 0.09 | 0.09 | 0.08 | |
Average Payables |
5.72 | 5.94 | 5.61 | 6.60 | |
Average Inventory |
0.22 | 0.21 | 0.24 | 0.30 | |
Average Assets |
79.26 | 79.85 | 95.52 | 90.06 | |
Average Common Equity |
9.81 | 29.02 | 43.26 | 44.98 |
Columns are period end dates